Skip to main content
Clinical Trials/NCT02183727
NCT02183727TerminatedPhase 2

L-C Ligament Versus Hamstring Autograft for Primary ACL Reconstruction: A Prospective, Randomized Controlled Trial

Soft Tissue Regeneration, Inc.1 site in 1 country60 target enrollmentStarted: September 1, 2015Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 2
Status
Terminated
Sponsor
Enrollment
60
Locations
1
Primary Endpoint
Physical Knee Function measured by the IKDC

Study Overview

Brief Summary

The purpose of this study is to compare safety and efficacy outcomes of the L-C Ligament versus Hamstring Autograft for treatment of acute rupture of the ACL.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 45 Years (Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patients with acute ruptures of the ACL who are willing to undergo treatment within 18 weeks of injury

Exclusion Criteria

  • •Prior ACL reconstruction or other surgical procedure on the affected (target) knee
  • •Chronic ACL injury; interventional surgery scheduled 127 days or more after ACL injury
  • •Professional athletes currently engaged in active sport
  • •Prior distal femoral and/or proximal tibial fracture(s) of the target leg
  • •Previous or current ACL injury on contra-lateral leg
  • •Multi-ligament reconstruction
  • •Malalignment or varus thrust
  • •Patient > 193 cm tall (6' 4")
  • •The patient does not follow pre-operative rehabilitation that may have been prescribed post-injury (prior to Index Procedure)
  • •Confirmed connective tissue disorder
  • •Signs of moderate to severe degenerative joint disease
  • •Severe pain, swelling, or redness within 24 hours prior to surgery
  • •Complete or partial Posterior Cruciate Ligament (PCL) tear
  • •If concomitant meniscal injury is present, any of the following: 1/3rd meniscal resection; complex double-bucket tear; partially repaired meniscal tears
  • •Any type of lateral and/or medial meniscal tear which is not repairable (<2mm from rim)
  • •Additional concomitant injuries to the knee or lower extremities requiring treatment, per surgeon's discretion, that are not allowable under the Inclusion criteria
  • •The patient is unwilling to not participate in sporting activities for at least 9 months post-procedure
  • •The patient is mentally compromised
  • •The patient has a neuromuscular disorder that would engender unacceptable risk of knee instability, prosthesis fixation failure, or complications in postoperative care
  • •The patient has an active or latent infection in or about the affected knee joint or an infection site distant from the knee that may spread to the knee hematogenously
  • •Pregnant based on a positive beta hCG serum or an in vitro diagnostic test result or breast-feeding
  • •The patient is obese with a BMI > 35
  • •The patient has a known allergy to PLLA
  • •The patient has a medical condition or comorbidity that would interfere with study participation

Arms & Interventions

L-C Ligament

Experimental

Soft Tissue Regeneration's L-C Ligament is an investigation, interventional device intended for ACL reconstruction surgery within 18 weeks of acute rupture of the ACL and no previous surgical treatment. The L-C Ligament temporarily replaces the human anterior cruciate ligament (ACL) and provides a bioresorbable scaffold within and around which the native ACL will regenerate over time.

Intervention: L-C Ligament (Device)

Hamstring Autograft

Active Comparator

Hamstring autograft is the active comparator for this study. Autograft tissue is the gold-standard treatment for primary ACL reconstruction.

Intervention: Hamstring Autograft (Procedure)

Outcomes

Primary Outcomes

Physical Knee Function measured by the IKDC

Time Frame: 12 Months

Physical Knee Function at 12 Months post procedure

Graft Failure

Time Frame: 12 Months

Revision surgery rate at one year

Secondary Outcomes

  • Pain Score(Day 1)
  • Adverse event rates(12 months)

Investigators

Sponsor
Soft Tissue Regeneration, Inc.
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials